Does Prior Exposure Affect Retention? A Real-World, Multicentre Assessment of IL-17 Inhibitor Cycling in Psoriatic Arthritis - PubMed
4 hours ago
- #Psoriatic Arthritis
- #Real-world Evidence
- #IL-17 Inhibitors
- Study evaluates real-world retention of IL-17 inhibitors (IL-17i) in psoriatic arthritis (PsA), focusing on prior exposure impact.
- Multicentre, retrospective study included 868 PsA patients (89.3% IL-17i-naïve) across 24 Italian rheumatology centres.
- Overall median IL-17i retention rates: 90.7% at 6 months, 77.5% at 12 months, 60.9% at 24 months, and 52.1% at 36 months.
- No significant difference in retention between IL-17i-naïve and IL-17i-experienced patients.
- Male sex and prior IL-17i exposure associated with lower discontinuation risk; axial involvement, more prior b/tsDMARDs, and later initiation year predicted poorer retention.
- Findings support sustained effectiveness of IL-17i therapy, suggesting cycling within the class remains a reasonable option for selected cases.